source
- Merck/Kelun ADC sac-TMT cuts death risk by one-third in advanced endometrial cancerA randomized Phase 3 trial showed that the antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT) reduced the risk of death by about one‑third in patients with advanced endometrial cancer. The…
- GSK gains another cancer drug approval and unveils promising chemo data as it prepares for lung cancer approvalGSK received regulatory approval this week for one of its cancer medicines in an additional tumor indication, expanding the portfolio that has grown since the company re-entered oncology a decade a…